[Anticancer activity of oxovanadium compounds]

Area of Science:

• Inorganic chemistry
• Medicinal chemistry
• Cell biology

Context:

• Vanadium compounds exhibit diverse biological activities.
• Developing novel anticancer agents with reduced toxicity is crucial.
• The structure-activity relationship of vanadium complexes needs further exploration.

Purpose:

• To evaluate the cytotoxic and antitumor activity of bis(L-malato)oxovanadium(IV) (VO(mal)2).
• To compare the efficacy of VO(mal)2 with other vanadium(IV) compounds, including vanadyl sulfate (VOSO4), VO(mal), and a vanadyl acetylacetonate complex.
• To assess the compound's toxicity towards normal human skin fibroblasts and its inhibitory effect on various cancer cell lines.

Summary:

• Bis(L-malato)oxovanadium(IV) (VO(mal)2) demonstrated significant inhibition of cancer cell growth (mouse fibrosarcoma L929, rat pheochromocytoma PC12, human liver carcinoma HepG2, virus-transformed mouse fibroblast NIN 3T3, and virus-transformed human kidney cells 293).
• VO(mal)2 exhibited low toxicity towards normal human skin fibroblasts.
• The observed cytotoxic and antitumor effects were dependent on incubation time, concentration, cell type, and the nature of the ligands coordinated to the oxovanadium(IV) center.

Impact:

• VO(mal)2 shows promise as a potential anticancer therapeutic due to its selective toxicity profile.
• This research contributes to understanding the therapeutic potential of organometallic vanadium complexes.
• Further investigation into VO(mal)2 could lead to the development of new cancer treatments.